XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.2
License Agreements - Lilly (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 175 Months Ended
Dec. 31, 2009
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
License Agreements            
Total revenues   $ 1,043,759 $ 954,610 $ 1,924,648 $ 1,763,283  
Eli Lilly | OLUMIANT            
License Agreements            
Total revenues   $ 31,700 $ 32,000 $ 62,300 $ 66,200  
Development Milestones | Eli Lilly            
License Agreements            
Amount recognized and received for the achievement of a predefined milestone           $ 149,000
Development Milestones | Maximum | Eli Lilly            
License Agreements            
Upfront and immediate milestone payment to be received under license agreement $ 150,000          
Regulatory Milestones | Eli Lilly            
License Agreements            
Amount recognized and received for the achievement of a predefined milestone           335,000
Regulatory Milestones | Maximum | Eli Lilly            
License Agreements            
Upfront and immediate milestone payment to be received under license agreement 365,000          
Commercialization Milestones | Eli Lilly            
License Agreements            
Amount recognized and received for the achievement of a predefined milestone           $ 50,000
Commercialization Milestones | Maximum | Eli Lilly            
License Agreements            
Upfront and immediate milestone payment to be received under license agreement $ 150,000